Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haley B Naik

Showing results (71-80 of 106) with videos related to

Pageof 11
Sort By:
Dermatology and Therapy|December 30, 2022
Real-World Findings on the Characteristics and Treatment Exposures of Patients with Hidradenitis Suppurativa from US Claims DataAmit Garg, Haley B Naik, Afsaneh Alavi, et al.
Skin Appendage Disorders|August 18, 2022
Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of ExpertsJonathan W Rick, Devea R De, Terri Shih, et al.
Biorxiv : the Preprint Server for Biology|March 9, 2026
Computational discovery of precision therapeutics for hidradenitis suppurativaErnest Y Lee, Phoebe Leboit, Haley B Naik, et al.
Journal of the American Academy of Dermatology|September 19, 2021
Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 RegistryHaley B Naik, Raed Alhusayen, John Frew, et al.
Dermatology (Basel, Switzerland)|December 25, 2022
Biologic Therapy Is Not Associated with Increased COVID-19 Severity in Patients with Hidradenitis Suppurativa: Updated Findings from the Global Hidradenitis Suppurativa COVID-19 RegistryJazzmin C Williams, Raed Alhusayen, Sandra Guilbault, et al.
American Journal of Clinical Dermatology|March 10, 2026
Defining Moderate Disease and Progression in Hidradenitis Suppurativa: An Expert Framework to Unlock the Window of Opportunity for Prompt TreatmentAntonio Martorell, John R Ingram, Christopher J Sayed, et al.
American Journal of Hematology|November 4, 2014
Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteriaZoya Kuzmina, Verena Gounden, Lauren Curtis, et al.
Journal of the American Academy of Dermatology|February 10, 2025
Patients with PSOriasis and Suppurative Hidradenitis (PSO-SH) share genetic risk factors and are at risk of increased morbidityAntonia Wiala, Kareem G Elhage, Andrea Leung, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2023
Tertiary Lymphoid Structures Sustain Cutaneous B cell Activity in Hidradenitis SuppurativaMargaret M Lowe, Jarish N Cohen, Madison I Moss, et al.
JCI Insight|August 26, 2020
Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-α therapyMargaret M Lowe, Haley B Naik, Sean Clancy, et al.
Pageof 11

Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
Dermatology and Therapy|December 30, 2022
Real-World Findings on the Characteristics and Treatment Exposures of Patients with Hidradenitis Suppurativa from US Claims DataAmit Garg, Haley B Naik, Afsaneh Alavi, et al.
Skin Appendage Disorders|August 18, 2022
Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of ExpertsJonathan W Rick, Devea R De, Terri Shih, et al.
Biorxiv : the Preprint Server for Biology|March 9, 2026
Computational discovery of precision therapeutics for hidradenitis suppurativaErnest Y Lee, Phoebe Leboit, Haley B Naik, et al.
Journal of the American Academy of Dermatology|September 19, 2021
Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 RegistryHaley B Naik, Raed Alhusayen, John Frew, et al.
Dermatology (Basel, Switzerland)|December 25, 2022
Biologic Therapy Is Not Associated with Increased COVID-19 Severity in Patients with Hidradenitis Suppurativa: Updated Findings from the Global Hidradenitis Suppurativa COVID-19 RegistryJazzmin C Williams, Raed Alhusayen, Sandra Guilbault, et al.
American Journal of Clinical Dermatology|March 10, 2026
Defining Moderate Disease and Progression in Hidradenitis Suppurativa: An Expert Framework to Unlock the Window of Opportunity for Prompt TreatmentAntonio Martorell, John R Ingram, Christopher J Sayed, et al.
American Journal of Hematology|November 4, 2014
Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteriaZoya Kuzmina, Verena Gounden, Lauren Curtis, et al.
Journal of the American Academy of Dermatology|February 10, 2025
Patients with PSOriasis and Suppurative Hidradenitis (PSO-SH) share genetic risk factors and are at risk of increased morbidityAntonia Wiala, Kareem G Elhage, Andrea Leung, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2023
Tertiary Lymphoid Structures Sustain Cutaneous B cell Activity in Hidradenitis SuppurativaMargaret M Lowe, Jarish N Cohen, Madison I Moss, et al.
JCI Insight|August 26, 2020
Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-α therapyMargaret M Lowe, Haley B Naik, Sean Clancy, et al.
Pageof 11